Is Shopify Stock a Good Buy Now?
eCommerce technology platform Shopify (NASDAQ:SHOP) delivered impressive returns in 2025…
Sell
27
NVCR Quote, Financials, Valuation and Earnings
Last price:
$14.33
Seasonality move
:
-4.99%
Day range:
$14.33 - $15.15
52-week range:
$10.70 - $28.56
Dividend yield:
0%
P/E ratio:
--
P/S ratio:
2.47x
P/B ratio:
4.71x
Volume:
1M
Avg. volume:
1.6M
1-year change:
-50.36%
Market cap:
$1.6B
Revenue:
$605.2M
EPS (TTM):
-$1.61
Price Performance History
Performance vs. Valuation Benchmarks
SEE THE 1% OF STOCKS YOU NEED TO OWN FOR MASSIVE RETURNS
GET BETTER TRADE IDEAS
Competitors
| Company | Revenue Forecast | Earnings Forecast | Revenue Growth Forecast | Earnings Growth Forecast | Analyst Price Target Median |
|---|---|---|---|---|---|
|
NVCR
NovoCure Ltd.
|
$168.4M | -$0.37 | 4.75% | -35.35% | $24.79 |
|
CATX
Perspective Therapeutics, Inc.
|
$147K | -$0.35 | -9.65% | -37.91% | $12.3077 |
|
INFU
InfuSystem Holdings, Inc.
|
$34.6M | $0.05 | 8.36% | 39.86% | $14.20 |
|
LIVN
LivaNova Plc
|
$338.8M | $0.90 | 6.94% | -20.8% | $73.00 |
|
VNRX
VolitionRX Ltd.
|
$806.3K | -$0.04 | 272.5% | -33.67% | $2.20 |
|
XTNT
Xtant Medical Holdings, Inc.
|
$28.5M | -- | -2.42% | -100% | $1.50 |
| Company | Price | Analyst Target | Market Cap | P/E Ratio | Dividend per Share | Dividend Yield | Price / LTM Sales |
|---|---|---|---|---|---|---|---|
|
NVCR
NovoCure Ltd.
|
$14.35 | $24.79 | $1.6B | -- | $0.00 | 0% | 2.47x |
|
CATX
Perspective Therapeutics, Inc.
|
$2.8400 | $12.3077 | $211.1M | -- | $0.00 | 0% | 192.56x |
|
INFU
InfuSystem Holdings, Inc.
|
$8.67 | $14.20 | $176.3M | 33.15x | $0.00 | 0% | 1.30x |
|
LIVN
LivaNova Plc
|
$64.41 | $73.00 | $3.5B | 38.16x | $0.00 | 0% | 2.61x |
|
VNRX
VolitionRX Ltd.
|
$0.33 | $2.20 | $40.9M | -- | $0.00 | 0% | 22.82x |
|
XTNT
Xtant Medical Holdings, Inc.
|
$0.68 | $1.50 | $95.5M | 66.86x | $0.00 | 0% | 0.74x |
| Company | Total Debt / Total Capital | Beta | Debt to Equity | Quick Ratio |
|---|---|---|---|---|
|
NVCR
NovoCure Ltd.
|
70.04% | 0.578 | 55.15% | 1.44x |
|
CATX
Perspective Therapeutics, Inc.
|
1.35% | 3.042 | 1.3% | 8.47x |
|
INFU
InfuSystem Holdings, Inc.
|
30.8% | 4.042 | 11.73% | 1.35x |
|
LIVN
LivaNova Plc
|
29.6% | 1.670 | 17.01% | 1.05x |
|
VNRX
VolitionRX Ltd.
|
-48.16% | 2.723 | 15.4% | 0.04x |
|
XTNT
Xtant Medical Holdings, Inc.
|
39.2% | 3.120 | 35.76% | 1.08x |
| Company | Gross Profit | Operating Income | Return on Invested Capital | Return on Common Equity | EBIT Margin | Free Cash Flow |
|---|---|---|---|---|---|---|
|
NVCR
NovoCure Ltd.
|
$122.5M | -$36M | -16.67% | -50.08% | -21.54% | $14.9M |
|
CATX
Perspective Therapeutics, Inc.
|
-$566K | -$27.9M | -37.13% | -37.63% | -13330.62% | -$18.3M |
|
INFU
InfuSystem Holdings, Inc.
|
$20.3M | $3.8M | 6.43% | 9.93% | 10.45% | $8.4M |
|
LIVN
LivaNova Plc
|
$244.9M | $56.6M | -12.15% | -18.29% | 15.83% | $62.2M |
|
VNRX
VolitionRX Ltd.
|
$318.2K | -$5.1M | -- | -- | -813.17% | -$3.5M |
|
XTNT
Xtant Medical Holdings, Inc.
|
$22M | $2.5M | 2.15% | 3.78% | 7.64% | $4.2M |
NovoCure Ltd. vs. Competitors
-
Which has Higher Returns NVCR or CATX?
Perspective Therapeutics, Inc. has a net margin of -22.29% compared to NovoCure Ltd.'s net margin of -12425.36%. NovoCure Ltd.'s return on equity of -50.08% beat Perspective Therapeutics, Inc.'s return on equity of -37.63%.
Company Gross Margin Earnings Per Share Invested Capital NVCRNovoCure Ltd.73.25% -$0.33 $1.1B CATXPerspective Therapeutics, Inc.-270.81% -$0.35 $245.5M -
What do Analysts Say About NVCR or CATX?
NovoCure Ltd. has a consensus price target of $24.79, signalling upside risk potential of 72.72%. On the other hand Perspective Therapeutics, Inc. has an analysts' consensus of $12.3077 which suggests that it could grow by 333.37%. Given that Perspective Therapeutics, Inc. has higher upside potential than NovoCure Ltd., analysts believe Perspective Therapeutics, Inc. is more attractive than NovoCure Ltd..
Company Buy Ratings Hold Ratings Sell Ratings NVCRNovoCure Ltd.4 2 0 CATXPerspective Therapeutics, Inc.12 1 0 -
Is NVCR or CATX More Risky?
NovoCure Ltd. has a beta of 0.735, which suggesting that the stock is 26.501% less volatile than S&P 500. In comparison Perspective Therapeutics, Inc. has a beta of 1.182, suggesting its more volatile than the S&P 500 by 18.151%.
-
Which is a Better Dividend Stock NVCR or CATX?
NovoCure Ltd. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Perspective Therapeutics, Inc. offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. NovoCure Ltd. pays -- of its earnings as a dividend. Perspective Therapeutics, Inc. pays out -- of its earnings as a dividend.
-
Which has Better Financial Ratios NVCR or CATX?
NovoCure Ltd. quarterly revenues are $167.2M, which are larger than Perspective Therapeutics, Inc. quarterly revenues of $209K. NovoCure Ltd.'s net income of -$37.3M is lower than Perspective Therapeutics, Inc.'s net income of -$26M. Notably, NovoCure Ltd.'s price-to-earnings ratio is -- while Perspective Therapeutics, Inc.'s PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for NovoCure Ltd. is 2.47x versus 192.56x for Perspective Therapeutics, Inc.. Usually stocks with elevated PS ratios are considered overvalued.
Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income NVCRNovoCure Ltd.2.47x -- $167.2M -$37.3M CATXPerspective Therapeutics, Inc.192.56x -- $209K -$26M
-
Which has Higher Returns NVCR or INFU?
InfuSystem Holdings, Inc. has a net margin of -22.29% compared to NovoCure Ltd.'s net margin of 6.19%. NovoCure Ltd.'s return on equity of -50.08% beat InfuSystem Holdings, Inc.'s return on equity of 9.93%.
Company Gross Margin Earnings Per Share Invested Capital NVCRNovoCure Ltd.73.25% -$0.33 $1.1B INFUInfuSystem Holdings, Inc.55.65% $0.11 $80.2M -
What do Analysts Say About NVCR or INFU?
NovoCure Ltd. has a consensus price target of $24.79, signalling upside risk potential of 72.72%. On the other hand InfuSystem Holdings, Inc. has an analysts' consensus of $14.20 which suggests that it could grow by 63.78%. Given that NovoCure Ltd. has higher upside potential than InfuSystem Holdings, Inc., analysts believe NovoCure Ltd. is more attractive than InfuSystem Holdings, Inc..
Company Buy Ratings Hold Ratings Sell Ratings NVCRNovoCure Ltd.4 2 0 INFUInfuSystem Holdings, Inc.5 0 0 -
Is NVCR or INFU More Risky?
NovoCure Ltd. has a beta of 0.735, which suggesting that the stock is 26.501% less volatile than S&P 500. In comparison InfuSystem Holdings, Inc. has a beta of 1.680, suggesting its more volatile than the S&P 500 by 68.01%.
-
Which is a Better Dividend Stock NVCR or INFU?
NovoCure Ltd. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. InfuSystem Holdings, Inc. offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. NovoCure Ltd. pays -- of its earnings as a dividend. InfuSystem Holdings, Inc. pays out -- of its earnings as a dividend.
-
Which has Better Financial Ratios NVCR or INFU?
NovoCure Ltd. quarterly revenues are $167.2M, which are larger than InfuSystem Holdings, Inc. quarterly revenues of $36.5M. NovoCure Ltd.'s net income of -$37.3M is lower than InfuSystem Holdings, Inc.'s net income of $2.3M. Notably, NovoCure Ltd.'s price-to-earnings ratio is -- while InfuSystem Holdings, Inc.'s PE ratio is 33.15x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for NovoCure Ltd. is 2.47x versus 1.30x for InfuSystem Holdings, Inc.. Usually stocks with elevated PS ratios are considered overvalued.
Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income NVCRNovoCure Ltd.2.47x -- $167.2M -$37.3M INFUInfuSystem Holdings, Inc.1.30x 33.15x $36.5M $2.3M
-
Which has Higher Returns NVCR or LIVN?
LivaNova Plc has a net margin of -22.29% compared to NovoCure Ltd.'s net margin of 7.49%. NovoCure Ltd.'s return on equity of -50.08% beat LivaNova Plc's return on equity of -18.29%.
Company Gross Margin Earnings Per Share Invested Capital NVCRNovoCure Ltd.73.25% -$0.33 $1.1B LIVNLivaNova Plc68.44% $0.49 $1.6B -
What do Analysts Say About NVCR or LIVN?
NovoCure Ltd. has a consensus price target of $24.79, signalling upside risk potential of 72.72%. On the other hand LivaNova Plc has an analysts' consensus of $73.00 which suggests that it could grow by 13.05%. Given that NovoCure Ltd. has higher upside potential than LivaNova Plc, analysts believe NovoCure Ltd. is more attractive than LivaNova Plc.
Company Buy Ratings Hold Ratings Sell Ratings NVCRNovoCure Ltd.4 2 0 LIVNLivaNova Plc6 2 0 -
Is NVCR or LIVN More Risky?
NovoCure Ltd. has a beta of 0.735, which suggesting that the stock is 26.501% less volatile than S&P 500. In comparison LivaNova Plc has a beta of 0.973, suggesting its less volatile than the S&P 500 by 2.741%.
-
Which is a Better Dividend Stock NVCR or LIVN?
NovoCure Ltd. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. LivaNova Plc offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. NovoCure Ltd. pays -- of its earnings as a dividend. LivaNova Plc pays out -- of its earnings as a dividend.
-
Which has Better Financial Ratios NVCR or LIVN?
NovoCure Ltd. quarterly revenues are $167.2M, which are smaller than LivaNova Plc quarterly revenues of $357.8M. NovoCure Ltd.'s net income of -$37.3M is lower than LivaNova Plc's net income of $26.8M. Notably, NovoCure Ltd.'s price-to-earnings ratio is -- while LivaNova Plc's PE ratio is 38.16x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for NovoCure Ltd. is 2.47x versus 2.61x for LivaNova Plc. Usually stocks with elevated PS ratios are considered overvalued.
Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income NVCRNovoCure Ltd.2.47x -- $167.2M -$37.3M LIVNLivaNova Plc2.61x 38.16x $357.8M $26.8M
-
Which has Higher Returns NVCR or VNRX?
VolitionRX Ltd. has a net margin of -22.29% compared to NovoCure Ltd.'s net margin of -862.39%. NovoCure Ltd.'s return on equity of -50.08% beat VolitionRX Ltd.'s return on equity of --.
Company Gross Margin Earnings Per Share Invested Capital NVCRNovoCure Ltd.73.25% -$0.33 $1.1B VNRXVolitionRX Ltd.50.73% -$0.05 -$24.7M -
What do Analysts Say About NVCR or VNRX?
NovoCure Ltd. has a consensus price target of $24.79, signalling upside risk potential of 72.72%. On the other hand VolitionRX Ltd. has an analysts' consensus of $2.20 which suggests that it could grow by 560.66%. Given that VolitionRX Ltd. has higher upside potential than NovoCure Ltd., analysts believe VolitionRX Ltd. is more attractive than NovoCure Ltd..
Company Buy Ratings Hold Ratings Sell Ratings NVCRNovoCure Ltd.4 2 0 VNRXVolitionRX Ltd.4 2 0 -
Is NVCR or VNRX More Risky?
NovoCure Ltd. has a beta of 0.735, which suggesting that the stock is 26.501% less volatile than S&P 500. In comparison VolitionRX Ltd. has a beta of 1.234, suggesting its more volatile than the S&P 500 by 23.404%.
-
Which is a Better Dividend Stock NVCR or VNRX?
NovoCure Ltd. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. VolitionRX Ltd. offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. NovoCure Ltd. pays -- of its earnings as a dividend. VolitionRX Ltd. pays out -- of its earnings as a dividend.
-
Which has Better Financial Ratios NVCR or VNRX?
NovoCure Ltd. quarterly revenues are $167.2M, which are larger than VolitionRX Ltd. quarterly revenues of $627.3K. NovoCure Ltd.'s net income of -$37.3M is lower than VolitionRX Ltd.'s net income of -$5.4M. Notably, NovoCure Ltd.'s price-to-earnings ratio is -- while VolitionRX Ltd.'s PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for NovoCure Ltd. is 2.47x versus 22.82x for VolitionRX Ltd.. Usually stocks with elevated PS ratios are considered overvalued.
Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income NVCRNovoCure Ltd.2.47x -- $167.2M -$37.3M VNRXVolitionRX Ltd.22.82x -- $627.3K -$5.4M
-
Which has Higher Returns NVCR or XTNT?
Xtant Medical Holdings, Inc. has a net margin of -22.29% compared to NovoCure Ltd.'s net margin of 3.93%. NovoCure Ltd.'s return on equity of -50.08% beat Xtant Medical Holdings, Inc.'s return on equity of 3.78%.
Company Gross Margin Earnings Per Share Invested Capital NVCRNovoCure Ltd.73.25% -$0.33 $1.1B XTNTXtant Medical Holdings, Inc.66.13% $0.01 $82.9M -
What do Analysts Say About NVCR or XTNT?
NovoCure Ltd. has a consensus price target of $24.79, signalling upside risk potential of 72.72%. On the other hand Xtant Medical Holdings, Inc. has an analysts' consensus of $1.50 which suggests that it could grow by 119.94%. Given that Xtant Medical Holdings, Inc. has higher upside potential than NovoCure Ltd., analysts believe Xtant Medical Holdings, Inc. is more attractive than NovoCure Ltd..
Company Buy Ratings Hold Ratings Sell Ratings NVCRNovoCure Ltd.4 2 0 XTNTXtant Medical Holdings, Inc.2 0 0 -
Is NVCR or XTNT More Risky?
NovoCure Ltd. has a beta of 0.735, which suggesting that the stock is 26.501% less volatile than S&P 500. In comparison Xtant Medical Holdings, Inc. has a beta of -0.077, suggesting its less volatile than the S&P 500 by 107.701%.
-
Which is a Better Dividend Stock NVCR or XTNT?
NovoCure Ltd. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Xtant Medical Holdings, Inc. offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. NovoCure Ltd. pays -- of its earnings as a dividend. Xtant Medical Holdings, Inc. pays out -- of its earnings as a dividend.
-
Which has Better Financial Ratios NVCR or XTNT?
NovoCure Ltd. quarterly revenues are $167.2M, which are larger than Xtant Medical Holdings, Inc. quarterly revenues of $33.3M. NovoCure Ltd.'s net income of -$37.3M is lower than Xtant Medical Holdings, Inc.'s net income of $1.3M. Notably, NovoCure Ltd.'s price-to-earnings ratio is -- while Xtant Medical Holdings, Inc.'s PE ratio is 66.86x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for NovoCure Ltd. is 2.47x versus 0.74x for Xtant Medical Holdings, Inc.. Usually stocks with elevated PS ratios are considered overvalued.
Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income NVCRNovoCure Ltd.2.47x -- $167.2M -$37.3M XTNTXtant Medical Holdings, Inc.0.74x 66.86x $33.3M $1.3M
SEE THE 1% OF STOCKS YOU NEED TO OWN FOR MASSIVE RETURNS
GET BETTER TRADE IDEAS
Popular
Will The Magnificent 7 Stocks Go Up This Year?
2025 was another banner year for the Magnificent Seven stocks,…
Why Did Planet Labs Stock Rally So Much?
Satellite imaging startup Planet Labs (NYSE:PL), after years of disappointing…
Stock Ideas
Buy
52
Is NVDA Stock a Buy?
Market Cap: $4.5T
P/E Ratio: 63x
Buy
65
Is GOOG Stock a Buy?
Market Cap: $4T
P/E Ratio: 41x
Buy
51
Is GOOGL Stock a Buy?
Market Cap: $4T
P/E Ratio: 41x
Alerts
Buy
100
ATGL alert for Jan 10
Alpha Technology Group Ltd. [ATGL] is up 47.05% over the past day.
Buy
71
NAIL alert for Jan 10
Direxion Daily Homebuilders & Supplies Bull 3X Shs [NAIL] is up 18.52% over the past day.
Buy
54
LGIH alert for Jan 10
LGI Homes, Inc. [LGIH] is up 13.81% over the past day.
